Nkarta Q3 2026 net loss widens 53% to $33.33 million
NKTX•Nkarta’s third-quarter 2026 net loss widened 53% year over year to $33.33 million, while research and development expenses rose 46% to $29.46 million. The company reported $216 million in cash, restricted cash and investments at September 30, with its operating plan funded into 2029.
1. Quarterly results
Nkarta’s third-quarter 2026 net loss widened 53% year over year to $33.33 million. Research and development expenses increased 46% to $29.46 million.
2. Cash and clinical plans
Cash, cash equivalents, restricted cash and investments totaled $216 million at September 30, and the operating plan is funded into 2029. Initial NKX019 clinical data in myositis and systemic sclerosis will be presented at ACR Convergence 2026; outpatient dosing is underway.
